RPTX
Repare·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RPTX
Repare Therapeutics Inc.
A leading clinical-stage precision oncology company that develops drugs for patients that target specific vulnerabilities of tumor cells
Biological Technology
09/06/2016
06/19/2020
NASDAQ Stock Exchange
129
12-31
Common stock
7171 Frederick-Banting, Building 2, Suite 270, St-Laurent, Québec, Canada H4S 1Z9
--
Repare Therapeutics Inc. was incorporated on September 6, 2016 under the Canadian Business Corporations Act. The Company is a leading precision oncology company with proprietary synthetic-killing methods for the discovery and development of novel therapies. Synthetic lethality, or SL, represents a clinically proven approach to drug development. The company uses its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies for genomic instability, including DNA damage repair. SL occurs when the deletion of either of the two genes is tolerated in the cell, but the simultaneous deletion of both genes leads to cell death. SL occurs when a deficiency of either of two genes in a cell is tolerated, but a simultaneous deficiency of both genes can lead to cell death. The company is using its SNIPRx platform to develop its pipeline of SL product candidates, including its product candidate RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Company Financials
EPS
RPTX has released its 2025 Q3 earnings. EPS was reported at 0.08, versus the expected -0.31, beating expectations. The chart below visualizes how RPTX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RPTX has released its 2025 Q3 earnings report, with revenue of 11.62M, reflecting a YoY change of NaN%, and net profit of 3.26M, showing a YoY change of 109.47%. The Sankey diagram below clearly presents RPTX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
